{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:18:39Z","timestamp":1788153519082,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Hand-Foot Syndrome (HFS) is a common side effect in patients undergoing chemotherapy, particularly with Doxorubicin and Docetaxel and can substantially impair quality of life. This study aimed to assess the feasibility and acceptability of using Ice Plant Intensive Cream (\n                      <jats:italic>Mesembryanthemum crystallinum<\/jats:italic>\n                      ) to prevent HFS in breast cancer patients, within a predefined recruitment target of 36 participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this randomized controlled pilot study, patients with breast cancer scheduled to receive treatment with doxorubicin or docetaxel were enrolled. Participants were randomly assigned either to an intervention group, which followed standard HFS prevention plus Ice Plant Intensive Cream to the hands and feet three times daily during chemotherapy, or a control group that received standard HFS prevention alone. Feasibility endpoints included recruitment rate, inclusion rate, retention, adherence to the intervention, and completeness of data collection. Secondary exploratory endpoints included HFS severity, skin-related symptoms, and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between January and November 2023, 330 patients were screened during tumor board meetings, of whom 58 met the eligibility criteria. Ultimately, 13 patients (22.4% of eligible) consented and were enrolled, indicating that neither the predefined recruitment target nor the randomization feasibility criterion were met. Most non-participation was attributable to patient overload during the diagnostic phase or initiation of chemotherapy before contact. Once enrolled, feasibility metrics related to retention, adherence, and data completeness were achieved, with a dropout rate of 15%, protocol adherence of 100% among participants who completed the study, and more than 90% completeness of scheduled assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The overall study was not feasible as designed, primarily due to recruitment limitations. However, once patients were enrolled, intervention procedures, data collection, and protocol adherence were fully feasible. Optimization of recruitment timing and earlier patient engagement during the diagnostic phase are recommended for future confirmatory trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT05755646<\/jats:ext-link>\n                      , identifier NCT05755646.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1758165","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:57Z","timestamp":1788150537000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility and acceptability of ice plant intensive cream in preventing hand-foot syndrome in breast cancer patients undergoing Doxorubicin and\/or Docetaxel therapy: a randomized controlled pilot study"],"prefix":"10.3389","volume":"16","author":[{"given":"Marcela","family":"Winkler","sequence":"first","affiliation":[{"name":"Department of Integrative Medicine, Robert Bosch Hospital","place":["Stuttgart, Germany"]},{"name":"Robert Bosch Center for Integrative Medicine and Health (RBIM), Robert Bosch Medical Research Society (RBMF), Bosch Health Campus (BHC)","place":["Stuttgart, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Arnhold","sequence":"additional","affiliation":[{"name":"Medical Faculty, University of T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Anheyer","sequence":"additional","affiliation":[{"name":"Robert Bosch Center for Integrative Medicine and Health (RBIM), Robert Bosch Medical Research Society (RBMF), Bosch Health Campus (BHC)","place":["Stuttgart, Germany"]},{"name":"Institute of General Practice and Interprofessional Care, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Idler","sequence":"additional","affiliation":[{"name":"Department of Integrative Medicine, Robert Bosch Hospital","place":["Stuttgart, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"L\u00f6ffler","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Robert Bosch Hospital","place":["Stuttgart, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Sauer","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Robert Bosch Hospital","place":["Stuttgart, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"L\u00f6ffler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, University Hospital of Wuerzburg","place":["Wuerzburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Cramer","sequence":"additional","affiliation":[{"name":"Robert Bosch Center for Integrative Medicine and Health (RBIM), Robert Bosch Medical Research Society (RBMF), Bosch Health Campus (BHC)","place":["Stuttgart, Germany"]},{"name":"Institute of General Practice and Interprofessional Care, University Hospital T\u00fcbingen","place":["T\u00fcbingen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2019.2165","article-title":"A systematic review and meta-analysis on the association between hand-foot syndrome (HFS) and cancer chemotherapy efficacy","volume":"170","author":"Falcone","year":"2019","journal-title":"Clin Ter"},{"key":"B3","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Breast Cancer, Version 3.2023"},{"key":"B4","unstructured":"Diagnosis and Treatment of Patients With Primary and Metastatic Breast Cancer: Recommendations 2025 of the AGO Breast Committee"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0033","article-title":"HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome","volume":"16","author":"Sibaud","year":"2011","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.23370","article-title":"Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: The SYSUCC-001 randomized clinical trial","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","unstructured":"Leitlinienprogramm Onkologie: Supportive Therapie Bei Onkologischen Patientinnen"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07175-3","article-title":"Prophylactic strategies for hand-foot syndrome\/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials","volume":"30","author":"Pandy","year":"2022","journal-title":"Supp Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: A randomized phase III trial of the AIO Quality of Life Working Group","volume":"33","author":"Hofheinz","year":"2015","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/jco.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000369909","article-title":"Mesembryanthemum crystallinum L. als dermatologisch wirksame Heilpflanze - erste Ergebnisse aus 3 Pilotstudien","volume":"21","author":"Raak","year":"2014","journal-title":"Forsch Komplementmed"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20543","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy221","article-title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","volume":"111","author":"Unger","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol28010084","article-title":"Integrative oncology education: An emerging competency for oncology providers","volume":"28","author":"Karim","year":"2021","journal-title":"Curr Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2012.03.002","article-title":"A randomised controlled pilot feasibility study of the physical and psychological effects of an integrated support programme in breast cancer","volume":"18","author":"Baker","year":"2012","journal-title":"Complement Ther Clin Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2009.01.002","article-title":"Personal physicians as study investigators: impact on patients' willingness to participate in clinical trials","volume":"30","author":"Sherber","year":"2009","journal-title":"Contemp Clin Trials"},{"key":"B21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12885-025-13684-1","article-title":"Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome","volume":"25","author":"Wongkraisri","year":"2025","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01730","article-title":"Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: A double-blind randomized controlled trial","volume":"42","author":"Santhosh","year":"2024","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1089\/acm.2021.0197","article-title":"Learning to fly: conceptions and misconceptions, uses and misuses of pilot studies in clinical research","volume":"27","author":"Cramer","year":"2021","journal-title":"J Altern Complement Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/cco.0000000000001150","article-title":"Implementing an integrative oncology pathway in a comprehensive cancer center: expert insights and perspectives","volume":"37","author":"Echterbille","year":"2025","journal-title":"Curr Opin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758165\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:28:59Z","timestamp":1788150539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1758165\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1758165"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1758165","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1758165"}}